Loading
Life sciences · Journal article
Scientific Journal of King Faisal University Basic and Applied Sciences · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Triple-negative breast cancer (TNBC) is an aggressive subtype defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, leaving limited targeted treatment options. In TNBC, TROP-2 (trophoblast cell surface antigen 2) is frequently overexpressed in TNBC and has been investigated as a potential biomarker and therapeutic target. This study primarily aimed to determine the prevalence and distribution of TROP-2 immunohistochemical expression in triple-negative breast cancer. Secondary exploratory analyses assessed associations between TROP-2 expression and available clinicopathological characteristics in an Egyptian cohort. In this retrospective cross-sectional study, 95 eligible TNBC cases underwent TROP-2 immunohistochemical assessment using the H-score method, with expression classified as negative (H-score = 0), low (H-score 1–99), intermediate (H-score 100–200), or high (H-score 201–300). Selected clinicopathological variables (tumour size, lymphovascular invasion, perineural invasion, pathological T/N stage, and neoadjuvant therapy) were available for 48 cases with accessible resection pathology records; extranodal extension was assessed among node-positive cases with evaluable lymph-node specimens ( n = 22). TROP-2 immunohistochemical assessment was performed on sections from the primary breast tumour; metastatic lymph-node deposits were not evaluated for TROP-2 expression. TROP-2 expression was identified in 87.4% of cases (83/95): 12.6% (12/95) were negative (H-score = 0), 16.8% (16/95) showed low expression (H-score 1–99), 25.3% (24/95) intermediate expression (H-score 100–200), and 45.3% (43/95) high expression (H-score 201–300).TROP-2 expression. TROP-2 expression categories were significantly associated with DCIS presence ( p = 0.042), Ki-67 index ( p = 0.001), extranodal extension ( p = 0.028), neoadjuvant therapy receipt ( p = 0.037), tumour-infiltrating lymphocytes (TILs; p = 0.049), and pathological T stage ( p = 0.038).Among resection cases ( n = 48), high TROP-2 expressors more frequently had T3-stage disease (34.8% vs. 0% in low expressors) and had received neoadjuvant therapy (34.8% vs. 0% in negative/low groups); extranodal extension was identified in 90.0% of node-positive high expressors vs. 25.0% of intermediate expressors ( n = 22). No significant association was observed between TROP-2 expression and lymphovascular invasion ( p = 0.056), histological grade ( p = 0.753), or nodal stage ( p = 0.432). TROP-2 expression was identified in 87.4% of TNBC cases in this Egyptian cohort and was associated with selected clinicopathological characteristics, including DCIS presence, pathological T stage, extranodal extension, Ki-67 index, tumour-infiltrating lymphocytes, and neoadjuvant therapy receipt. However, owing to the retrospective cross-sectional design, incomplete availability of selected clinicopathological variables, and absence of survival or treatment-response outcomes, these findings should be interpreted as exploratory associations and do not establish prognostic or predictive value. Larger prospective multicenter studies incorporating standardised TROP-2 immunohistochemical assessment, survival endpoints, and therapeutic-response data are needed to determine the clinical relevance of TROP-2 expression in TNBC.